PSMA-Targeted Radiolabeled Peptide for Imaging and Therapy in Prostate Cancer: Preclinical Evaluation of Biodistribution and Therapeutic Efficacy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157580 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ming-Wei Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Economic Affairs, ROC.
Abstract (Originalsprache)
Albumin-binding agents enhance tumor uptake of radiopharmaceuticals targeting prostate-specific membrane antigens (PSMAs) in radiotherapy. We synthesized PSMA-NARI-56, a molecule with both PSMA targeting activity and albumin-binding moiety, labeled with 177Lu as the therapeutic agent. The aim of this study was to determine the specific binding of 177Lu-PSMA-NARI-56 towards PSMA, assess its biodistribution, and evaluate therapeutic effectiveness by tumor-bearing mice. The effect of 177Lu-PSMA-NARI-56 viability of PSMA-positive cell (LNCaP) was evaluated. Biodistribution and endoradiotherapy studies were utilized to determine the distribution, targeting, and anti-tumor efficacy by tumor-bearing mice identified by 111In-PSMA-NARI-56. 177Lu-PSMA-NARI-56 exhibited a significant impact on the viability of the LNCaP cell. Biodistribution results revealed the maximum tumor uptake of 177Lu-PSMA-NARI-56 occurring within 24 h, reaching 40.56 ± 10.01%ID/g. In radionuclide therapy, at 58 days post-injection (p.i.), 177Lu-PSMA-NARI-56 demonstrated superior tumor inhibition (98%) compared to 177Lu-PSMA-617 (58%), and the mouse survival rate after 90 days of radiotherapy (90%) was also higher than that of 177Lu-PSMA-617 (30%) in LNCaP tumor-bearing mice. In the PSMA-positive animal model, 177Lu-PSMA-NARI-56 shows higher potential radiotheranostic and prolonged accumulation (identify by 111In-PSMA-NARI-56/nanoSPECT/CT image), offering the potential for improved treatment effectiveness and increased survival rates when compared to 177Lu-PSMA-617.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan.
- Taipei Neuroscience Institute & Laboratory Animal Center, Taipei Medical University, Taipei 110301, Taiwan.
ORCID-Profile: Ming-Wei Chen, Shih-Ying Lee, Kang-Wei Chang
Förderung
- Ministry of Economic Affairs, ROC
Zitieren
APA
Chen, M. W., Huang, Y. R., Lo, W. L., Lee, S. Y., Lo, S. N., Wang, S. M., & Chang, K. W. (2025). PSMA-Targeted Radiolabeled Peptide for Imaging and Therapy in Prostate Cancer: Preclinical Evaluation of Biodistribution and Therapeutic Efficacy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157580
Vancouver
Chen MW, Huang YR, Lo WL, Lee SY, Lo SN, Wang SM, et al. PSMA-Targeted Radiolabeled Peptide for Imaging and Therapy in Prostate Cancer: Preclinical Evaluation of Biodistribution and Therapeutic Efficacy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157580
BibTeX
@article{Chen2025,
author = {Chen, Ming-Wei and Huang, Yuan-Ruei and Lo, Wei-Lin and Lee, Shih-Ying and Lo, Sheng-Nan and Wang, Shih-Ming and Chang, Kang-Wei},
title = {PSMA-Targeted Radiolabeled Peptide for Imaging and Therapy in Prostate Cancer: Preclinical Evaluation of Biodistribution and Therapeutic Efficacy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157580}
}
EUVIMED